Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results From CALGB 80203 (Alliance)

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-14-2313
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

PTEN Loss of Expression Predicts Cetuximab Efficacy in Metastatic Colorectal Cancer Patients

British Journal of Cancer
Cancer ResearchOncology
2007English

Cetuximab in First Line Treatment of Metastatic Colorectal Cancer

Farmeconomia. Health economics and therapeutic pathways
2012English

Mechanism of Resistance to Cetuximab Therapy in Colorectal Cancer

mAbs
AllergyImmunology
2012English

Current Status of Treatment of Metastatic Colorectal Cancer With Special Reference to Cetuximab and Elderly Patients

OncoTargets and Therapy
OncologyPharmacology
2008English

Safety and Efficacy of the Addition of Simvastatin to Cetuximab in Previously Treated KRAS Mutant Metastatic Colorectal Cancer Patients

Investigational New Drugs
OncologyPharmacology
2015English

Molecular Targeted Treatment of Metastatic Colorectal Cancer: The Cardiovascular Adverse Effects of Bevacizumab and Cetuximab

Medicine and Pharmacy Reports
Medicine
2017English

Systematic Review and Economic Evaluation of Bevacizumab and Cetuximab for the Treatment of Metastatic Colorectal Cancer

Health Technology Assessment
MedicineHealth Policy
2007English

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Evolving Role of Cetuximab in the Treatment of Colorectal Cancer

Cancer Management and Research
Oncology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy